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Abstract 
Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show 
sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated 
the patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour 
infusion. Methods: A total of 243 patients with ID were randomized alternatively to receive iron 
polymaltose infusion either as a 2-hour infusion or as a 4-hour infusion. All patients received pre-
medication with certizine hydrochloride 10 mg PO one-hour before infusion and hydrocortisone 50 mg IVI 
immediately before infusion. Infusion related adverse events/side-effects during the infusion and over the 
next seven days were documented and graded as mild, moderate or severe. Results: The age of the 
patients ranged from 17 years to 92 years (mean 55.5 yr); M:F = 1:3.5. One hundred and twenty-two 
patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were in the 4-hour arm (M:F = 1:2.6; 
mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients in both arms. Adverse 
events/side effects were documented in 14 patients in each arm (22 events in the 2-hour arm and 20 in 
the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal cramps, 
rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild 
and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron 
polymaltose is similar to that observed with 4-hour infusion of iron polymaltose. 
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ABSTRACT 
Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show 
sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated the 
patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour infusion. Meth- 
ods: A total of 243 patients with ID were randomized alternatively to receive iron polymaltose infusion either as 
a 2-hour infusion or as a 4-hour infusion. All patients received pre-medication with certizine hydrochloride 10 
mg PO one-hour before infusion and hydrocortisone 50 mg IVI immediately before infusion. Infusion related 
adverse events/side-effects during the infusion and over the next seven days were documented and graded as 
mild, moderate or severe. Results: The age of the patients ranged from 17 years to 92 years (mean 55.5 yr); M:F = 
1:3.5. One hundred and twenty-two patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were 
in the 4-hour arm (M:F = 1:2.6; mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients 
in both arms. Adverse events/side effects were documented in 14 patients in each arm (22 events in the 2-hour 
arm and 20 in the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal 
cramps, rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild 
and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron poly- 
maltose is similar to that observed with 4-hour infusion of iron polymaltose. 
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1. Introduction 
Iron deficiency (ID) state, with or without anaemia, is a 
common problem worldwide afflicting all age groups for 
varying reasons. [1] Optimum management of patients 
with ID requires identification and treatment of the cause, 
as well as iron supplementation therapy, the latter gener- 
ally given orally. However, there are several practical 
problems with oral iron therapy, e.g. gastro-intestinal 
side effects, poor absorption and poor patient compliance. 
[2] Patients with one or more of these problems are can- 
didates for consideration of parenteral iron therapy. Sev- 
eral recent reports have documented the efficacy and 
safety of total dose intravenous iron infusion therapy, 
making it the preferred parenteral route [3-5]. In Aus- 
tralia iron polymaltose is the only agent currently PBS 
(pharmaceutical benefit scheme) listed, given mostly as a 
4-hour infusion. [5,6] In the present study, we have 
compared the safety and patient tolerance of 2-hour ver- 
sus 4-hour infusion of total dose iron polymaltose in 243 
patients. 
2. Material and Methods 
During a six month period (April-September, 2012) 243 *Corresponding author. 
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patients with proven ID and deemed unsuitable for oral 
iron therapy were randomized to receive total dose (500 
mg - 1000 mg) iron polymaltose intravenous therapy 
either as a 2-hour infusion or as a 4-hour infusion. The 
patients had been referred to one of the Consultant Cli- 
nical Haematologists for assessment and consideration of 
parenteral iron supplementation therapy. The rationale 
for the study was discussed with each patient by the 
Consultant Clinical Haematologist and the patients who 
had agreed to participate were randomized alternatively 
to the 2-hour arm or the 4-hour arm on the day of treat- 
ment by a reception staff member of the treating day care 
centre. Patients with the following medical history/pro- 
blems were excluded from the study: hypersensitivity to 
iron, first trimester of pregnancy, severe inflammatory 
bowel disease, severe renal or liver disease, heart failure, 
bronchial asthma, history of severe allergic reactions and 
impending or recent surgery. The study was approved by 
the Human Resources Ethics Committee, University of 
Wollongong (HE 12/88) and all the participating patients 
had signed the required consent form. 
Patients were routinely given pre-medication with cer- 
tizine hydrochloride 10 mg PO one hour before the infu- 
sion and hydrocortisone 50 mg IVI immediately before 
commencement of the infusion. Iron polymaltose (500 
mg - 1000 mg) was diluted in 500 ml of normal saline 
and the infusion was commenced at 50 mls per hour for 
10 minutes in all patients. After ensuring that there are no 
anaphylactic reactions, the rate of infusion was increased 
to 125 mls per hour for patients in the 4-hour group; and, 
to 250 mls per hour for patients in the 2-hour group. 
They were closely monitored with periodic pulse and 
blood pressure measurements and for hypersensitivity 
reactions such as urticarial rash, itching, nausea and fever 
or shivering. 
The nursing staff in the treating day care centre closely 
monitored the patients during the infusion and docu- 
mented any adverse events. Subsequently, the patients 
were contacted one and seven days after the infusion to 
obtain information of possible delayed reactions: fever, 
arthralgia, myalgia, light headedness, headache, metallic 
taste, nausea, vomiting, diarrhoea and rash. The adverse 
events during and after the infusion were graded as mild 
(no observable patient discomfort/no activity limitation), 
moderate (observable patient discomfort/some activity 
limitation) or severe (distress or requiring medical assis- 
tance) [7]. 
3. Results 
A total of 243 patients were recruited over a six month 
period from two centres (Sydney and Wollongong). The 
age of the patients ranged from 17 years to 92 years 
(mean 55.5 yr); M:F = 1:3.5. One hundred and twenty- 
two patients (M:F = 1:5; mean age 52.9 yr) received the 
iron infusion over a 2-hour period, whilst the other 121 
patients (M:F = 1:2.6; mean age 58.1 yr) received the 
infusion over a 4-hour period. Iron infusion therapy was 
generally well tolerated and the majority of patients (in 
both arms) who returned to the clinical haematologists 
for follow-up reported an improved sense of wellbeing l - 
7 days after the infusion. 
The reported side-effects/adverse events in the 2-hour 
infusion arm and the 4-hour infusion arm are shown in 
Table 1. Fourteen of the 122 patients in the 2-hour infu-
sion arm reported 22 side-effects/adverse events. Some 
of the side-effects (aches and pains, cannula-site pain/ 
swelling, nausea and abdominal cramps) lasted for more 
than 24 hours, whilst the others (rash, vagal response and 
metallic taste) were transient, lasting for less than one 
hour. In 12 of the 14 patients, the side-effects were mild; 
two patients had moderate aches and pains. None had 
any severe side-effects. 
 
Table 1. Reports of adverse events. 
 2-Hour infusion:  14/122 patients 
4-Hour infusion:  
14/121 patients 
 Mild Moderate Severe Mild Moderate Severe 
All 20 2 0 17 3 0 
During  
infusion       
Aches and 
pains    2 0 0 
Hot flushes    1 0 0 
Rash 1 0 0    
Vagal  
response 1 0 0 1 0 0 
24 Hrs 
post-infusion       
Abdominal 
cramps    1 0 0 
Aches and 
pains 5 1 0 2 0 0 
Cannula site 
pain/swelling 1 0 0 1 1 0 
Headache    2 0 0 
Metallic taste 2 0 0    
Nausea 2 0 0    
Day 1-7 
post-infusion       
Abdominal 
cramps 1 0 0    
Aches and 
pains 5 1 0 4 1 0 
Cannula site 
pain/swelling 1 0 0 1 1 0 
Headache    2 0 0 
Nausea 1 0 0    
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Fourteen of the 121 patients in the 4-hour infusion arm 
reported 20 side effects (Table 1). None of the side-ef- 
fects was severe. Hot flushes, vagal response and ab- 
dominal cramps were mild and transient. Aches and 
pains lasted for less than 24 hours in two patients. In five 
patients this symptom lasted for more than 24 hours; in 
one of these patients this symptom was graded as “mod- 
erate”. Two patients had cannula site pain and swelling 
which lasted for more than 24 hours; one “mild” and one 
“moderate”. Two patients reported headache lasting for 
more than 24 hours—one “mild”, one “moderate”. 
4. Discussion 
Iron polymaltose therapy was well tolerated and the 
overall incidence of adverse events/side effects was low. 
There was no significant difference between the 2-hour 
infusion group and the 4-hour infusion group. In most of 
the patients (12/14, 11/14, respectively) the side-effects 
were mild; none had any severe side-effects. As the study 
was specifically designed to assess and compare the 
safety and patient tolerance and, a large proportion of the 
patients who participated in the study had returned to 
their regular medical practitioners for on-going care, data 
relating to the efficacy of iron polymaltose infusion were 
not routinely collected. 
Our experience with the 2-hour infusion of iron poly- 
maltose is comparable to that reported by Garg et al. [7] 
The latter authors administered iron polymaltose as a 
58-minute infusion after an initial 15-minute test dose 
without pre-medication to 100 patients and documented 
34 side-effects in 24 patients during infusion and 31 side- 
effects in 26 patients during the 5-day post-infusion pe- 
riod. The presence of inflammatory bowel disease was 
associated with a higher incidence of side-effects during 
the infusion. None of the patients in our study had severe 
inflammatory bowel disease and they were routinely 
given pre-medication with cetirizine hydrochloride orally 
(one hour before infusion) and hydrocortisone IVI (im- 
mediately before infusion). These two differences may 
explain the lower incidence of side-effects documented 
in our study. However, we note that the potential benefi- 
cial role of pre-medication is controversial. A retrospec- 
tive study of 386 patients by Newnham et al. [8] had 
shown no difference in the incidence of adverse events in 
patients receiving premedication (92 patients) compared 
to those (294 patients) who did not receive pre-medica- 
tion. 
Iron carboxymaltose (Ferric carboxymaltose) is an- 
other iron preparation which can be used for intravenous 
infusion therapy. This product can be given as a high- 
dose (500 mg - 1000 mg) drip infusion over a 15 minute 
period. Although currently available in Australia, this 
product is not in the Pharmaceutical Benefit Scheme 
(PBS) list and so, is more expensive ($176.95 for 500 mg) 
than iron polymaltose ($50.36 for 500 mg) [9]. The re- 
ported side-effects with iron carboxymaltose infusion are 
similar to those documented with iron polymaltose infu- 
sion: headaches, nausea, rash, dizziness, local injection 
site reactions, abdominal pain, diarrhoea and vomiting 
[10]. 
To the best of our knowledge, there are no reported 
studies comparing the rate of adverse events/side-effects 
between iron polymaltose infusion and iron carboxymal- 
tose infusion. There are also no randomized studies to 
assess the benefits of pre-medication in patients receiving 
total dose iron infusion therapy. These reservations not- 
withstanding, the cumulative experience to date, has led 
to widespread and increasing use of total-dose iron infu- 
sion therapy as an effective, convenient and well-toler- 
ated alternative for patients with ID who are deemed to 
be in need of parenteral iron therapy [11,12]. Infusions 
over shorter periods will enable Day Care Centres to treat 
more patients, thus reducing the patient waiting time and 
also making the treatment more cost-effective. 
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